Search Results

Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.

• Authors : Molinelli, Elisa¹ (AUTHOR) ; Simonetti, Oriana¹ (AUTHOR)

Subjects: HIDRADENITIS suppurativa

• Source: Lancet. Jun2024, Vol. 403 Issue 10443, p2457-2459. 3p.

Record details

Biotech UCB Mimics Obesity Drug Stocks With Skin Disease Focus.

• Authors : Pham, Lisa (AUTHOR)

Subjects: HIDRADENITIS suppurativa; ALZHEIMER'S disease; IMMUNOLOGIC diseases

• Source: Bloomberg.com. 10/8/2024, pN.PAG-N.PAG. 1p.

Record details

Secukinumab treatment of hidradenitis suppurativa: questions remain.

• Authors : Maul, Julia-Tatjana^1,2 (AUTHOR) ; Kolios, Antonios G A¹ (AUTHOR); Thomsen, Simon Francis^3,4 (AUTHOR)

Subjects: HIDRADENITIS suppurativa

• Source: Lancet. Feb2024, Vol. 403 Issue 10427, p616-617. 2p.

Record details

Secukinumab treatment of hidradenitis suppurativa: questions remain – Authors' reply.

• Authors : Kimball, Alexa B¹ (AUTHOR) ; Ravichandran, Shoba² (AUTHOR)

Subjects: HIDRADENITIS suppurativa; AUTHORS

• Source: Lancet. Feb2024, Vol. 403 Issue 10427, p617-618. 2p.

Record details

The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.

• Authors : Egeberg, Alexander^1,2 (AUTHOR) ; Thyssen, Jacob P^1,2 (AUTHOR)

Subjects: HIDRADENITIS suppurativa; THERAPEUTICS

• Source: Lancet. Mar2023, Vol. 401 Issue 10378, p708-710. 3p.

Record details

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.

• Authors : Kimball, Alexa B¹ (AUTHOR) ; Jemec, Gregor B E^1,2,3,4 (AUTHOR); Sayed, Christopher J^4,5 (AUTHOR)

Subjects: HIDRADENITIS suppurativa; CLINICAL trials; THRUSH (Mouth disease)UCB SA UCB SA UCB SA 043546522

• Source: Lancet. Jun2024, Vol. 403 Issue 10443, p2504-2519. 16p.

Record details

Secukinumab treatment of hidradenitis suppurativa: questions remain.

• Authors : Endo, Michioki¹ (AUTHOR) ; Kami, Masahiro² (AUTHOR)

Subjects: HIDRADENITIS suppurativa

• Source: Lancet. Feb2024, Vol. 403 Issue 10427, p617-617. 1p.

Record details

Incyte sinks on setback for drugs acquired in $750M buyout.

• Authors : Fidler, Ben (AUTHOR)

Subjects: *BIOTECHNOLOGY industries; HIDRADENITIS suppurativa; GRAFT versus host disease

• Source: BioPharma Dive. 11/19/2024, pN.PAG-N.PAG. 1p.

Record details

Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug.

• Authors : Waldron, James (AUTHOR)

Subjects: *MERGERS & acquisitions; HIDRADENITIS suppurativa; DRUGSELI Lilly & Co. ELI Lilly & Co. ELI Lilly & Co. LLY

• Source: FierceBiotech. 3/28/2024, pN.PAG-N.PAG. 1p.

Record details

Hidradenitis suppurativa: lutikizumab.

Subjects: HIDRADENITIS suppurativa; CLINICAL trials; KNEE osteoarthritis

• Source: Manufacturing Chemist. Apr2024, Vol. 95 Issue 4, p30-30. 1/2p.

Record details